Shares of Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) were down 10% during trading on Tuesday . The stock traded as low as $29.58 and last traded at $29.25. Approximately 2,645,742 shares changed hands during mid-day trading, an increase of 133% from the average daily volume of 1,137,116 shares. The stock had previously closed at $32.51.
Analyst Ratings Changes
Several research firms have issued reports on PCVX. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim restated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Bank of America lowered their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $136.50.
View Our Latest Report on PCVX
Vaxcyte Stock Up 11.3 %
The company's 50 day moving average price is $66.40 and its 200 day moving average price is $85.73. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of -6.78 and a beta of 1.26.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
Insider Buying and Selling at Vaxcyte
In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,250 shares of company stock worth $3,170,738. Company insiders own 3.10% of the company's stock.
Institutional Trading of Vaxcyte
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PCVX. Rhumbline Advisers boosted its stake in shares of Vaxcyte by 5.5% during the 1st quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock worth $6,843,000 after acquiring an additional 9,416 shares in the last quarter. Parallel Advisors LLC grew its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after purchasing an additional 1,071 shares during the period. GAMMA Investing LLC increased its position in shares of Vaxcyte by 2,631.8% in the first quarter. GAMMA Investing LLC now owns 9,780 shares of the company's stock valued at $369,000 after buying an additional 9,422 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Vaxcyte by 17.5% during the 4th quarter. California State Teachers Retirement System now owns 105,052 shares of the company's stock worth $8,600,000 after buying an additional 15,616 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Vaxcyte in the 4th quarter worth $8,487,000. Institutional investors and hedge funds own 96.78% of the company's stock.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
